Cargando…
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590686/ https://www.ncbi.nlm.nih.gov/pubmed/34775463 http://dx.doi.org/10.1038/s41408-021-00551-y |
| _version_ | 1784599036656877568 |
|---|---|
| author | Galtier, Jean Alric, Camille Bérard, Emilie Leguay, Thibaut Tavitian, Suzanne Bidet, Audrey Delabesse, Eric Rieu, Jean Baptiste Vial, Jean-Philippe Vergez, François Lechevalier, Nicolas Luquet, Isabelle Klein, Emilie de Grande, Anne-Charlotte Sarry, Audrey Pigneux, Arnaud Récher, Christian Bertoli, Sarah Dumas, Pierre-Yves |
| author_facet | Galtier, Jean Alric, Camille Bérard, Emilie Leguay, Thibaut Tavitian, Suzanne Bidet, Audrey Delabesse, Eric Rieu, Jean Baptiste Vial, Jean-Philippe Vergez, François Lechevalier, Nicolas Luquet, Isabelle Klein, Emilie de Grande, Anne-Charlotte Sarry, Audrey Pigneux, Arnaud Récher, Christian Bertoli, Sarah Dumas, Pierre-Yves |
| author_sort | Galtier, Jean |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8590686 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85906862021-11-17 Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes Galtier, Jean Alric, Camille Bérard, Emilie Leguay, Thibaut Tavitian, Suzanne Bidet, Audrey Delabesse, Eric Rieu, Jean Baptiste Vial, Jean-Philippe Vergez, François Lechevalier, Nicolas Luquet, Isabelle Klein, Emilie de Grande, Anne-Charlotte Sarry, Audrey Pigneux, Arnaud Récher, Christian Bertoli, Sarah Dumas, Pierre-Yves Blood Cancer J Correspondence Nature Publishing Group UK 2021-11-13 /pmc/articles/PMC8590686/ /pubmed/34775463 http://dx.doi.org/10.1038/s41408-021-00551-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Galtier, Jean Alric, Camille Bérard, Emilie Leguay, Thibaut Tavitian, Suzanne Bidet, Audrey Delabesse, Eric Rieu, Jean Baptiste Vial, Jean-Philippe Vergez, François Lechevalier, Nicolas Luquet, Isabelle Klein, Emilie de Grande, Anne-Charlotte Sarry, Audrey Pigneux, Arnaud Récher, Christian Bertoli, Sarah Dumas, Pierre-Yves Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes |
| title | Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes |
| title_full | Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes |
| title_fullStr | Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes |
| title_full_unstemmed | Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes |
| title_short | Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes |
| title_sort | intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590686/ https://www.ncbi.nlm.nih.gov/pubmed/34775463 http://dx.doi.org/10.1038/s41408-021-00551-y |
| work_keys_str_mv | AT galtierjean intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT alriccamille intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT berardemilie intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT leguaythibaut intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT tavitiansuzanne intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT bidetaudrey intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT delabesseeric intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT rieujeanbaptiste intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT vialjeanphilippe intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT vergezfrancois intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT lechevaliernicolas intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT luquetisabelle intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT kleinemilie intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT degrandeannecharlotte intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT sarryaudrey intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT pigneuxarnaud intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT recherchristian intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT bertolisarah intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT dumaspierreyves intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes |